Evan E. Opas

Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis

Richard A. F. Dixon, Ronald E. Diehl, Evan E. Opas et al. · Nature · 1990 · 776 citations

Life Sciences, Biochemistry, Pharmacology +10

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.

R. Balena, Brian C. Toolan, M. Shea et al. · Journal of Clinical Investigation · 1993 · 399 citations · Full text

Medicine, Animal Sciences, Endocrinology +17

L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-<i>t</i>-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor

John W. Gillard, A W Ford‐Hutchinson, Chi-Chung Chan et al. · Canadian Journal of Physiology and Pharmacology · 1989 · 328 citations

Medicine, Biochemistry, Pharmacology +14

Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate.

A. Schmidt, Su Jane Rutledge, Naoto Endo et al. · Proceedings of the National Academy of Sciences · 1996 · 193 citations

Medicine, Biochemistry, Molecular Biology +17

Differential effects of calmodulin antagonists on phospholipases A2 and C in thrombin-stimulated platelets.

Ronald W. Walenga, Evan E. Opas, Maurice B. Feinstein · Journal of Biological Chemistry · 1981 · 151 citations · Full text

Medicine, Cell Biology, Pharmacology +17